Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
152.28B
Market cap152.28B
Price-Earnings ratio
19.37
Price-Earnings ratio19.37
Dividend yield
6.55%
Dividend yield6.55%
Average volume
34.61M
Average volume34.61M
High today
$26.91
High today$26.91
Low today
$26.26
Low today$26.26
Open price
$26.39
Open price$26.39
Volume
13.76M
Volume13.76M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$21.97
52 Week low$21.97

Stock Snapshot

As of today, Pfizer(PFE) shares are valued at $26.77. The company's market cap stands at 152.28B, with a P/E ratio of 19.37 and a dividend yield of 6.5%.

During the trading session on 2026-04-30, Pfizer(PFE) shares reached a daily high of $26.91 and a low of $26.26. At a current price of $26.77, the stock is +1.9% higher than the low and still -0.5% under the high.

Trading volume for Pfizer(PFE) stock has reached 13.76M, versus its average volume of 34.61M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $21.97.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $21.97.

PFE News

Nasdaq 8h
Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead?

Key Points High-yield stocks may offer impressive levels of passive income -- but it’s important to understand why the particular stock is high-yield. Dividen...

Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead?
Benzinga 21h
Pfizer Says Cancer Therapy Beats Standard Therapy In Late-Stage Blood Cancer Study

Pfizer Inc. (NYSE:PFE) on Wednesday shared topline results from the late-stage study of its cancer treatment, ELREXFIO (elranatamab). Multiple myeloma is an agg...

Pfizer Says Cancer Therapy Beats Standard Therapy In Late-Stage Blood Cancer Study
TipRanks 23h
Pfizer’s Ritlecitinib Trial Targets Painful Skin Disease, Adding Quiet Upside to PFE’s Pipeline

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions...

Analyst ratings

50%

of 30 ratings
Buy
40%
Hold
50%
Sell
10%

More PFE News

TipRanks 1d
Pfizer reports ‘positive’ results from Phase 3 MagnetisMM-5 study

Pfizer (PFE) announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO as monotherapy in adults with relapsed or refractory mul...

Simply Wall St 1d
Is Pfizer Offering Value After Recent Share Price Weakness?

If you are wondering whether Pfizer's current share price reflects its true worth, starting with the recent share performance and valuation checks can help fram...

Is Pfizer Offering Value After Recent Share Price Weakness?
Nasdaq 2d
Should You Buy, Sell, or Hold Pfizer at $27?

Key Points Pfizer's growth rate has tanked in recent years, and investors remain concerned about the future. The company has been loading up on acquisitions t...

Should You Buy, Sell, or Hold Pfizer at $27?
TipRanks 2d
BridgeBio jumps 12% to $83.18 as Pfizer confirms tafamidis settlement

10:18 EDT BridgeBio (BBIO) jumps 12% to $83.18 as Pfizer (PFE) confirms tafamidis settlement Published first on TheFly – the ultimate source for real-time, mar...

TipRanks 2d
Pfizer announces three settlement agreements for Vyndamax

Pfizer (PFE) announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regard...

TipRanks 2d
Pfizer Kept at Hold as Pipeline Uncertainty and LOE Risks Temper Upside, Price Target Cut to $26

Analyst Asad Haider of Goldman Sachs maintained a Hold rating on Pfizer, reducing the price target to $26.00. Claim 55% Off TipRanks Unlock hedge fund-level dat...

Simply Wall St 3d
Pfizer Valuation Check After New Oncology Data And Priority Review For Cancer Regimen

Pfizer (PFE) is back in focus after unveiling extensive new oncology data at the American Society of Clinical Oncology meeting and securing FDA Priority Review...

Pfizer Valuation Check After New Oncology Data And Priority Review For Cancer Regimen

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.